{
  "_metadata": {
    "version": "2.0",
    "ticker": "EWTX",
    "asset_name": "edg7500",
    "source": "CIRRUS-HCM Phase 2 Poster, CVCT Forum Dec 2025",
    "data_cutoff": "May 2025 (preliminary)",
    "extraction_date": "2026-02-04"
  },
  "asset": {
    "name": "EDG-7500",
    "ticker": "EWTX",
    "modality": "Small molecule cardiac sarcomere modulator",
    "stage": "Phase 2",
    "one_liner": "First-in-class cardiac sarcomere modulator for HCM that slows acto-myosin engagement without inactivating myosin, avoiding the LVEF reductions seen with cardiac myosin inhibitors",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "Cardiac Sarcomere (Acto-Myosin)",
    "full_name": "Cardiac sarcomere acto-myosin complex",
    "class": "Sarcomere modulator",
    "pathway": "Acto-myosin cross-bridge cycling → cardiac contraction → hypercontractility in HCM",
    "biology": {
      "simple_explanation": "EDG-7500 is a novel cardiac sarcomere modulator designed to slow the rate of acto-myosin engagement and speed disengagement WITHOUT inactivating the myosin motor head. This is fundamentally different from cardiac myosin inhibitors (CMIs) which stabilize the super-relaxed state by inactivating myosin.",
      "mechanism_detail": {
        "acto_myosin_engagement": "Slows the rate of engagement in early systole",
        "acto_myosin_disengagement": "Speeds disengagement in early diastole",
        "myosin_motor_head": "Does NOT inactivate - preserves cardiac myosin function",
        "result": "Improved ventricular filling without compromising systolic function"
      },
      "vs_cmi": {
        "cmi_mechanism": "Stabilize super-relaxed (SRX) state by inactivating myosin, decreasing myosin-actin cross-bridge formation",
        "cmi_problem": "Might cause systolic dysfunction and require careful LVEF monitoring through frequent echocardiographic evaluation",
        "edg7500_advantage": "No meaningful reductions in LVEF observed across the development program - potentially could eliminate the need for safety echocardiograms"
      }
    },
    "why_good_target": {
      "clinical_validation": "Sarcomere modulation validated by mavacamten (CAMZYOS) and aficamten in oHCM",
      "preclinical_evidence": "In preclinical studies and Phase 2 single-dose oHCM study, EDG-7500 demonstrated significant reductions in LVOT-G and NT-proBNP along with improvements in diastolic function",
      "unmet_need": [
        "CMIs cause systolic dysfunction requiring frequent echo monitoring",
        "Mavacamten requires REMS with echos every 4-12 weeks",
        "nHCM has NO approved therapies"
      ]
    }
  },
  "clinical_data": {
    "trial_name": "CIRRUS-HCM",
    "full_title": "A Multiple-Dose Phase 2 Study of Safety, Tolerability, and Effects on Hemodynamics and Functional Capacity of the Novel Cardiac Sarcomere Modulator EDG-7500 in Hypertrophic Cardiomyopathy",
    "trial_design": {
      "phase": "Phase 2",
      "design": "Multiple-dose, open-label",
      "endpoints": "Safety, tolerability, pharmacokinetics, pharmacodynamics",
      "doses_tested": ["50 mg", "100 mg"],
      "duration": "4 weeks",
      "data_status": "Preliminary data as of May 2025"
    },
    "investigators": {
      "lead_author": "Anjali T Owens",
      "co_authors": ["Theodore P Abraham", "Ronald Wharton", "Ankit Bhatia", "Mariko W Harper", "Christopher Dufton", "Daniel D Gretler", "Jeffrey A Silverman", "Marilyn M Mok", "Molly Madden", "James MacDougall", "Natalie Hawryluk", "Marc J Semigran"],
      "institutions": [
        {"number": 1, "name": "University of Pennsylvania, Philadelphia PA"},
        {"number": 2, "name": "University of California, San Francisco CA"},
        {"number": 3, "name": "Northwell Health, New Hyde Park NY"},
        {"number": 4, "name": "The Christ Hospital Health Network, Cincinnati OH"},
        {"number": 5, "name": "Virginia Mason Franciscan Health, Seattle WA"},
        {"number": 6, "name": "Edgewise Therapeutics, Boulder CO"}
      ]
    },
    "populations": {
      "ohcm": {
        "n": 17,
        "definition": "Obstructive HCM - thickened heart muscle blocks blood flow out through LVOT"
      },
      "nhcm": {
        "n": 12,
        "definition": "Nonobstructive HCM - thickened muscle without significant outflow blockage"
      },
      "combined": {
        "n": 29
      }
    },
    "baseline_characteristics": {
      "ohcm": {
        "n": 17,
        "age_years_mean_sd": "61 (13)",
        "female_n_pct": "12 (71%)",
        "bmi_kg_m2_mean_sd": "28 (4)",
        "pathogenic_sarcomere_variant_n_pct": "4 (24%)",
        "history_paroxysmal_af_flutter_n_pct": "1 (6%)",
        "icd_n_pct": "2 (12%)",
        "prior_srt_n_pct": "1 (6%)",
        "hypertension_n_pct": "11 (65%)",
        "diabetes_n_pct": "1 (6%)",
        "nyha_class_i_n_pct": "1 (6%)",
        "nyha_class_ii_n_pct": "10 (59%)",
        "nyha_class_iii_n_pct": "6 (35%)",
        "lvef_pct_mean_sd": "65 (4)",
        "lvot_g_resting_mmhg_mean_sd": "59 (30)",
        "lvot_g_valsalva_mmhg_mean_sd": "93 (32)",
        "e_prime_cm_s_mean_sd": "6 (2)",
        "maximal_lv_wall_thickness_mm_mean_sd": "18 (2)",
        "lavi_ml_m2_mean_sd": "37 (13)",
        "kccq_oss_mean_sd": "63 (16)",
        "kccq_css_mean_sd": "69 (15)",
        "nt_probnp_geometric_mean": 724,
        "nt_probnp_median": 710,
        "nt_probnp_iqr": "381, 1074"
      },
      "nhcm": {
        "n": 12,
        "age_years_mean_sd": "54 (19)",
        "female_n_pct": "7 (58%)",
        "bmi_kg_m2_mean_sd": "27 (4)",
        "pathogenic_sarcomere_variant_n_pct": "4 (33%)",
        "history_paroxysmal_af_flutter_n_pct": "2 (17%)",
        "icd_n_pct": "6 (50%)",
        "prior_srt_n_pct": "0 (0%)",
        "hypertension_n_pct": "2 (17%)",
        "diabetes_n_pct": "2 (17%)",
        "nyha_class_i_n_pct": "0 (0%)",
        "nyha_class_ii_n_pct": "6 (50%)",
        "nyha_class_iii_n_pct": "6 (50%)",
        "lvef_pct_mean_sd": "61 (6)",
        "lvot_g_resting_mmhg_mean_sd": "9 (6)",
        "lvot_g_valsalva_mmhg_mean_sd": "14 (10)",
        "e_prime_cm_s_mean_sd": "7 (2)",
        "maximal_lv_wall_thickness_mm_mean_sd": "18 (3)",
        "lavi_ml_m2_mean_sd": "31 (12)",
        "kccq_oss_mean_sd": "57 (22)",
        "kccq_css_mean_sd": "63 (23)",
        "nt_probnp_geometric_mean": 782,
        "nt_probnp_median": 715,
        "nt_probnp_iqr": "546, 1231"
      }
    },
    "baseline_characteristics_explained": {
      "study_populations": {
        "ohcm": "Obstructive HCM - thickened heart muscle blocks blood flow out of the heart through the LVOT",
        "nhcm": "Non-obstructive HCM - thickened heart muscle without significant outflow blockage",
        "key_observation": "Groups are reasonably well-matched except for expected obstruction differences (LVOT-G), ensuring treatment effects aren't due to baseline imbalances"
      },
      "variable_definitions": {
        "demographics": {
          "age_sex_bmi": "Basic patient characteristics - both groups mostly female, similar BMI ~27-28 kg/m2",
          "pathogenic_sarcomere_variant": "Confirmed genetic mutation causing disease - 24-33% have identified mutations; remainder may be polygenic or unidentified"
        },
        "cardiac_history": {
          "af_flutter": "Atrial fibrillation/flutter history - irregular heartbeat increasing stroke risk",
          "icd": "Implantable cardioverter-defibrillator - device for dangerous arrhythmias. Notably HIGHER in nHCM (50% vs 12%) reflecting higher arrhythmia risk despite no obstruction",
          "prior_srt": "Prior septal reduction therapy - surgical myectomy or alcohol ablation",
          "hypertension_diabetes": "Common cardiovascular comorbidities"
        },
        "heart_function": {
          "nyha_class": {
            "definition": "New York Heart Association functional classification",
            "class_i": "No limitation of physical activity",
            "class_ii": "Slight limitation - comfortable at rest but ordinary activity causes symptoms",
            "class_iii": "Marked limitation - comfortable at rest but less than ordinary activity causes symptoms",
            "study_finding": "59% NYHA II and 35% NYHA III in oHCM; 50%/50% split in nHCM - moderate to severe symptoms"
          },
          "lvef": {
            "definition": "Left ventricular ejection fraction - percentage of blood pumped out each heartbeat",
            "normal_range": "55-70%",
            "study_values": "65% oHCM, 61% nHCM - both NORMAL, typical for HCM (systolic function preserved)",
            "key_relevance": "EDG-7500's differentiator is maintaining LVEF vs CMIs which can reduce it"
          },
          "lvot_g": {
            "definition": "Left ventricular outflow tract gradient - pressure difference showing obstruction",
            "normal": "<30 mmHg at rest",
            "ohcm_threshold": "≥30 mmHg rest or ≥50 mmHg with provocation",
            "study_values_ohcm": "59 mmHg rest, 93 mmHg Valsalva",
            "study_values_nhcm": "9 mmHg rest, 14 mmHg Valsalva",
            "interpretation": "Confirms proper oHCM vs nHCM classification"
          },
          "e_prime": {
            "definition": "Early diastolic mitral annular velocity - measures how well heart RELAXES (diastolic function)",
            "normal": ">8 cm/s",
            "study_values": "6-7 cm/s - IMPAIRED in both groups",
            "key_relevance": "Key treatment target - EDG-7500 improves e' within 1 week"
          },
          "max_lv_wall_thickness": {
            "definition": "Maximum thickness of left ventricular wall",
            "normal": "<12 mm",
            "hcm_threshold": "≥15 mm (or ≥13 mm with family history)",
            "study_values": "18 mm both groups - confirms HCM diagnosis"
          },
          "lavi": {
            "definition": "Left atrial volume index - LA size adjusted for body size",
            "normal": "<34 ml/m2",
            "study_values": "37 ml/m2 oHCM, 31 ml/m2 nHCM - mild enlargement in oHCM",
            "relevance": "LA enlargement reflects chronic elevated filling pressures and predicts AF risk"
          }
        },
        "quality_of_life_biomarkers": {
          "kccq": {
            "definition": "Kansas City Cardiomyopathy Questionnaire - patient-reported QoL",
            "oss": "Overall Summary Score (0-100, higher = better)",
            "css": "Clinical Summary Score (0-100, higher = better)",
            "study_values": "57-69 range - moderately impaired QoL",
            "mcid": "5 points minimum clinically important difference"
          },
          "nt_probnp": {
            "definition": "N-terminal pro-B-type natriuretic peptide - blood marker of cardiac wall stress",
            "normal": "<125 pg/mL (age-adjusted)",
            "study_values": "710-715 pg/mL median - ELEVATED indicating significant cardiac strain",
            "relevance": "56% achieved normalization (<150 pg/mL) at 100mg; strong correlation with pVO2 improvement"
          }
        }
      },
      "key_baseline_observations": {
        "icd_difference": "50% ICD rate in nHCM vs 12% in oHCM suggests nHCM patients may have higher arrhythmia burden despite lacking obstruction",
        "similar_symptoms": "Both groups have similar NYHA class distribution and QoL impairment, supporting need for treatment in BOTH populations",
        "diastolic_dysfunction": "Impaired e' in both groups (6-7 cm/s vs normal >8) confirms diastolic dysfunction is common target regardless of obstruction status"
      }
    },
    "efficacy_ohcm": {
      "lvot_gradient": {
        "section_title": "LVOT-G at Rest & Post Valsalva",
        "baseline_note": "5 participants had either resting gradients <30 mmHg or Valsalva gradients <50 mmHg on Day 1",
        "n_with_week4_data": {
          "50mg": 7,
          "100mg": 9
        },
        "resting_lvot_g": {
          "endpoint": "% Reaching Resting LVOT-G <30 mmHg at Week 4",
          "50mg": "43%",
          "100mg": "89%"
        },
        "valsalva_lvot_g": {
          "endpoint": "% Reaching Valsalva LVOT-G <50 mmHg at Week 4",
          "50mg": "57%",
          "100mg": "89%"
        },
        "complete_response_definition": "Resting and Valsalva gradients <30 mmHg and <50 mmHg, respectively",
        "data_presentation": "Mean ± SEM"
      },
      "nt_probnp": {
        "section_title": "NT-proBNP",
        "percent_change_100mg": "~82% reduction (Mean ≈ 82%)",
        "normalization": {
          "endpoint": "Achieved NT-proBNP <150 pg/mL at 100mg",
          "result": "5/9 (56%)"
        },
        "correlation_note": "Improvements in NT-proBNP have shown a strong correlation to improvements in pVO2",
        "reference": "Coats CJ et al., Eur Heart J 2024 Nov 8;45(42)"
      },
      "e_prime_diastolic_function": {
        "section_title": "Early Diastolic Mitral Annular Velocity (e')",
        "baseline_mean": "6.1 cm/s",
        "key_finding": "Rapid dose-responsive improvements in mean e' observed as early as 1 week after initiation of treatment with EDG-7500",
        "timepoint_data": {
          "week_2_vs_baseline": {
            "50mg_p_value": "NS",
            "100mg_p_value": "≤0.05",
            "50mg_change": "+27%",
            "100mg_change": "+27%"
          },
          "week_4_vs_baseline": {
            "50mg_p_value": "≤0.05",
            "100mg_p_value": "NS"
          }
        },
        "data_presentation": "Mean ± SD for baseline value; Mean ± SEM for % change from baseline"
      },
      "kccq": {
        "section_title": "KCCQ-OSS and KCCQ-CSS 4 Weeks vs. Baseline",
        "n_evaluated_week4": "7 individuals",
        "kccq_oss": {
          "median_improvement_50mg": "7 points",
          "median_improvement_100mg": "2 points"
        },
        "kccq_css": {
          "median_improvement_50mg": "2 points",
          "median_improvement_100mg": "2 points"
        },
        "p_values": "p = NS at both doses across both KCCQ measures at Week 4",
        "kccq_css_100mg_distribution": {
          "section_title": "KCCQ-CSS 100mg after 4 Weeks vs. Baseline",
          "very_large_improvement_gte20_points": "46.7%",
          "large_improvement_15_to_20_points": "11.1%",
          "moderate_improvement_10_to_15_points": "11.1%",
          "small_improvement_5_to_10_points": "17.8%",
          "minimal_change_or_worsening": "13.3%"
        },
        "clinical_improvement_overall": "89% with Clinical Improvements"
      },
      "nyha_class": {
        "section_title": "NYHA Functional Class",
        "n_evaluated_week4_50mg": 7,
        "n_evaluated_week4_100mg": 5,
        "50mg_dose_group": {
          "baseline_class_ii": "43%",
          "baseline_class_iii": "57%",
          "week_2_class_i": "29%",
          "week_2_class_ii": "43%",
          "week_2_class_iii": "29%",
          "week_4_class_i": "14%",
          "week_4_class_ii": "43%",
          "week_4_class_iii": "14%",
          "eos_class_i": "0%",
          "eos_class_ii": "57%",
          "eos_class_iii": "0%"
        },
        "100mg_dose_group": {
          "baseline_class_ii": "67%",
          "baseline_class_iii": "22%",
          "week_2_class_i": "11%",
          "week_2_class_ii": "56%",
          "week_2_class_iii": "11%",
          "week_4_class_i": "57%",
          "week_4_class_ii": "22%",
          "week_4_class_iii": "11%"
        },
        "improvement_gte1_class_week4": {
          "50mg": "43%",
          "100mg": "78%"
        },
        "note": "* Represents 7 individuals evaluated for NYHA at week 4 (50mg); * Represents patients evaluated by NYHA at week 2 (100mg)"
      }
    },
    "efficacy_nhcm": {
      "nt_probnp": {
        "section_title": "NT-proBNP",
        "key_finding": "EDG-7500 treatment resulted in rapid and robust reductions in NT-proBNP in participants with nHCM",
        "percent_change_from_baseline": {
          "50mg_week1": "~30% reduction",
          "50mg_week2": "~40% reduction",
          "50mg_week4": "~48% reduction",
          "100mg_week1": "~50% reduction",
          "100mg_week2": "~55% reduction",
          "100mg_week4": "~64% reduction"
        },
        "note": "Mean ± SEM"
      },
      "e_prime_diastolic_function": {
        "section_title": "Early Diastolic Mitral Annular Velocity (e')",
        "baseline_mean": "7.1 cm/s",
        "key_finding": "Treatment with EDG-7500 led to mean e' changes in participants with nHCM as early as one week following initiation of dosing",
        "timepoint_data": {
          "week_2_vs_baseline": {
            "p_value": "0.05 at both doses"
          },
          "week_4_vs_baseline": {
            "note": "Two participants at week 4",
            "p_value": "NS at both doses"
          }
        },
        "data_presentation": "Mean ± SD for baseline value; Mean ± SEM for % change from baseline"
      },
      "kccq": {
        "section_title": "KCCQ-CSS 50mg and 100mg after 4 Weeks vs. Baseline",
        "50mg_dose_group": {
          "median_improvement": "12 points",
          "note": "4/8 at baseline; 1/8 not evaluated at baseline and/or EOS (end of study)"
        },
        "100mg_dose_group": {
          "median_improvement": "17 points"
        },
        "kccq_css_distribution": {
          "very_large_improvement_gte20_points": "25.9%",
          "large_improvement_15_to_20_points": "17.3%",
          "moderate_improvement_10_to_15_points": "13.0%",
          "small_improvement_5_to_10_points": "9.9%",
          "minimal_change_or_worsening": "33.9%"
        },
        "clinical_improvement_overall": "88% with Clinical Improvements"
      }
    },
    "safety": {
      "section_title": "oHCM and nHCM: Safety Summary",
      "lvef_findings": {
        "main_finding": "No Meaningful Reductions in LVEF or LVEF<50% Across a Broad Exposure Range Observed After EDG-7500 Treatment",
        "pooled_analysis": {
          "description": "Pooled Healthy Volunteer and CIRRUS Data",
          "result": "No correlation between EDG-7500 plasma concentration (ng/mL) and LVEF change from baseline",
          "concentration_range_tested": "0 to >1200 ng/mL"
        },
        "nhcm_low_baseline_lvef": {
          "finding": "4/12 (33%) participants with nHCM had a baseline LVEF <60% by core lab",
          "outcome": "All 4 remained stable throughout the treatment period",
          "lvef_below_50": "No LVEF below 50%",
          "change_from_baseline": "+2.5% for the 4 nHCM participants"
        },
        "ohcm_lvef_changes": {
          "50mg_week2": "+1.2%",
          "50mg_week4": "-3.2%",
          "100mg_week2": "-2.1%",
          "100mg_week4": "+1.2%"
        }
      },
      "treatment_emergent_adverse_events": {
        "total_n": 29,
        "note": "Treatment-emergent adverse events in >1 participant in the combined oHCM and nHCM cohorts",
        "events": [
          {"event": "Dizziness", "n": 8, "pct": "27.6%", "note": "mostly mild and transient in duration"},
          {"event": "Upper respiratory tract infection", "n": 5, "pct": "17.2%"},
          {"event": "Atrial fibrillation", "n": 4, "pct": "13.8%", "note": "see details below"},
          {"event": "Influenza like illness", "n": 3, "pct": "10.3%"},
          {"event": "Palpitations", "n": 3, "pct": "10.3%"},
          {"event": "Constipation", "n": 2, "pct": "6.9%"},
          {"event": "Diarrhea", "n": 2, "pct": "6.9%"},
          {"event": "Headache", "n": 2, "pct": "6.9%"}
        ],
        "atrial_fibrillation_detail": {
          "total": "4 participants (3 oHCM, 1 nHCM) had new onset symptomatic atrial fibrillation",
          "saes": "Two of these events were considered SAEs",
          "lvef_note": "None of the patients who had atrial fibrillation experienced LVEF <50% at any time"
        },
        "discontinuation": {
          "n": 1,
          "detail": "One oHCM participant discontinued treatment due to moderate dizziness"
        }
      }
    },
    "conclusions": {
      "from_poster": [
        "EDG-7500 has the potential to emerge as an exciting new therapeutic option for both oHCM and nHCM",
        "EDG-7500 treatment appears to be generally well tolerated across a broad exposure range without meaningful impact on LVEF",
        "Treatment with EDG-7500 was shown to improve LVOT-G, NT-proBNP, e', KCCQ, and NYHA",
        "In the longer-term cohort of CIRRUS-HCM, intra-patient dose optimization is being explored"
      ]
    }
  },
  "disease_background": {
    "hcm_overview": {
      "definition": "Hypertrophic cardiomyopathy (HCM) is characterized by enhanced cardiac actin-myosin cross-bridge cycling, leading to hypercontractility, myocardial hypertrophy, fibrosis, and diastolic dysfunction",
      "prevalence": "Most common inherited cardiac condition; ~1 in 500 people",
      "us_patients": "~600,000 patients in US"
    },
    "ohcm_phenotype": {
      "definition": "Obstructive HCM - combination of hypercontractility, hypertrophy, small LV cavity, and abnormal mitral valve apparatus leading to LVOT obstruction",
      "prevalence": "2/3 of HCM patients (~200,000 US)",
      "pathophysiology": "LVOT gradient ≥30 mmHg at rest or ≥50 mmHg with provocation"
    },
    "nhcm_phenotype": {
      "definition": "Nonobstructive HCM - ventricular hypertrophy without significant LVOT obstruction",
      "prevalence": "1/3 of HCM patients (~400,000 US)",
      "unmet_need": "NO approved therapies - underserved population"
    }
  },
  "current_treatment_landscape": {
    "first_line": {
      "agents": "Non-vasodilating beta-blockers (metoprolol, propranolol, nadolol)",
      "mechanism": "Decrease calcium entry, reduce heart rate, prolong diastolic filling",
      "limitations": "No RCT evidence; do not modify disease"
    },
    "second_line": {
      "agents": "Non-dihydropyridine calcium channel blockers (verapamil, diltiazem)",
      "limitations": "No RCT evidence; do not modify disease"
    },
    "third_line": {
      "agent": "Disopyramide",
      "limitations": "QTc prolongation, anticholinergic effects, tachyphylaxis"
    },
    "cardiac_myosin_inhibitors": {
      "class_overview": "First drug class targeting underlying HCM pathophysiology",
      "mechanism": "Inhibit cardiac myosin ATPase to stabilize super-relaxed state",
      "mavacamten": {
        "brand": "CAMZYOS",
        "approval": "FDA approved oHCM NYHA II-III",
        "safety_concern": "LVEF <50% in up to 13.8%; requires REMS with frequent echos",
        "price": "$89,500/year US"
      },
      "aficamten": {
        "status": "Under regulatory review",
        "safety": "LVEF <50% in 5.3%"
      },
      "edg7500_differentiation": "No meaningful LVEF reductions - may eliminate need for safety echocardiograms"
    }
  },
  "catalysts": [
    {
      "event": "Longer-term CIRRUS-HCM data with intra-patient dose optimization",
      "timing": "2026",
      "importance": "high",
      "what_to_watch": "Durability of efficacy; continued LVEF safety; optimal dosing strategy"
    },
    {
      "event": "Phase 3 trial initiation",
      "timing": "TBD",
      "importance": "critical",
      "what_to_watch": "Trial design for oHCM and/or nHCM populations; endpoints; comparator"
    }
  ],
  "competitive_landscape": {
    "competitors": [
      {
        "drug": "mavacamten (CAMZYOS)",
        "company": "Bristol-Myers Squibb",
        "limitation": "REMS required; LVEF <50% up to 13.8%; $89,500/year; oHCM only"
      },
      {
        "drug": "aficamten",
        "company": "Cytokinetics",
        "limitation": "LVEF <50% in 5.3%; oHCM only; will require monitoring"
      }
    ],
    "our_advantages": [
      "No meaningful LVEF reductions - may eliminate need for REMS/frequent echos",
      "Active in BOTH oHCM AND nHCM (nHCM has 400K US patients with zero approved therapies)",
      "Different mechanism preserves myosin function",
      "Rapid diastolic improvement (e') within 1 week",
      "89% clinical improvement oHCM; 88% nHCM"
    ]
  },
  "investment_analysis": {
    "bull_case": [
      "No LVEF reductions - eliminates major CMI safety liability; may not need REMS/frequent echos",
      "Only therapy targeting nHCM (400K US patients with ZERO approved options)",
      "89% LVOT-G response at 100mg; 56% achieved NT-proBNP normalization",
      "78% had ≥1 NYHA class improvement at 100mg - strong symptomatic benefit",
      "Differentiated mechanism preserves myosin function vs CMIs that inactivate myosin",
      "Rapid diastolic improvement within 1 week differentiates from competitors"
    ],
    "bear_case": [
      "Small Phase 2 (N=29) - safety advantage needs larger trial confirmation",
      "Mavacamten and aficamten already approved/launching",
      "Atrial fibrillation in 13.8% (4/29, 2 SAEs) higher than expected",
      "nHCM regulatory path unvalidated",
      "Commercial execution risk as emerging company"
    ],
    "probability_of_success": "De-risked by Phase 2 but larger trials needed",
    "peak_sales_estimate": "$2-4B+ if successful in oHCM + nHCM",
    "key_risks": [
      "Small Phase 2 sample size",
      "CMI competitors have head start",
      "AF signal needs monitoring",
      "nHCM regulatory path unclear"
    ]
  },
  "market_opportunity": {
    "tam": "$2-4B (CMI class)",
    "patient_population": "600,000 US (200K oHCM, 400K nHCM)",
    "unmet_need": "nHCM has NO approved therapies; oHCM therapies have significant monitoring burden"
  },
  "abbreviations": {
    "AF": "atrial fibrillation",
    "BMI": "body mass index",
    "e_prime": "early diastolic mitral annular velocity",
    "CSS": "clinical summary score",
    "EOS": "end of study",
    "HCM": "hypertrophic cardiomyopathy",
    "ICD": "implantable cardioverter-defibrillator",
    "KCCQ": "Kansas City Cardiomyopathy Questionnaire",
    "LAVI": "left atrial volume index",
    "LV": "left ventricular",
    "LVEF": "LV ejection fraction",
    "LVOT": "LV outflow tract",
    "LVOT_G": "LVOT gradient",
    "NS": "not significant",
    "NT_proBNP": "N-terminal pro-B-type natriuretic peptide",
    "NYHA": "New York Heart Association",
    "oHCM": "obstructive HCM",
    "nHCM": "nonobstructive HCM",
    "OSS": "overall summary score",
    "pVO2": "peak oxygen consumption",
    "SRT": "septal reduction therapy",
    "SEM": "standard error of the mean",
    "SD": "standard deviation"
  }
}
